Cereno Scientific’s Phase II trial with CS1 in Pulmonary Arterial Hypertension is closing for recruitment and proceeding to topline
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Phase II trial with CS1 in the rare disease Pulmonary Arterial Hypertension (PAH), is closing for recruitment and proceeding to topline.Based on a recommendation from the Study Clinical Steering Committee, Cereno Scientific has decided to close patient recruitment to study CS1-003 by July 1st, 2024. The Study Clinical Steering Committee concluded that there is sufficient data for evaluating the next steps in development.
To meet the increasing need for fossil-free energy, Vattenfall is continuing to investigate the possibilities of the restoration and renewal of Juktan pumped power station. AFRY has contributed to the environmental impact statement and technical description for the application to the Land and Environment Court and has been awarded a contract for further work with the plant design of the pumped power station.Juktan's power station is located between lakes Storjuktan and Storuman in the upper part of the Umeälven, in northern parts of Sweden. The power plant was the first and largest pumped
